Complete Filing Data
Chemomab Therapeutics Ltd. reported Stockholders Equity of $12.33 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Chemomab Therapeutics Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income * | -$9.0M | -$13.9M | -$24.2M | -$27.6M | -$12.5M | -$6.0M | -$27.1M | -$13.8M |
| Research And Development Expense | $5.8M | $11.3M | $18.4M | $17.0M | $6.3M | $4.7M | $13.3M | $7.5M |
| General And Administrative Expense | $3.7M | $3.4M | $7.1M | $11.6M | $6.0M | $1.3M | $6.2M | $5.5M |
| Operating Expenses | $9.6M | $14.7M | $25.5M | $28.5M | $12.4M | $6.0M | $22.9M | $13.0M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$9.0M | -$13.9M | -$24.2M | -$28.2M | -$12.5M | $27.1M | $13.5M | |
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | -$534.0K | $0.00 | $306.0K | ||
| Income Taxes Paid Net | $5.0K | $0.00 | $84.0K | $161.0K | $244.0K | |||
| Net Income Losses | -$11.6M | -$27.1M | ||||||
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | ||||||||
| Nonoperating Income Expense | $572.0K | $794.0K | $1.2M | $353.0K | -$111.0K | |||
| Income Taxes Received | $0.00 | $0.00 | $187.0K | $351.0K | $0.00 | |||
| Restructuring Charges | $749.0K | $3.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$8.8M | -$8.1M | -$6.2M | -$5.1M | -$3.0M | -$2.8M | -$1.7M | -$1.2M | -$1.1M | -$1.7M | -$7.2M | -$4.4M | -$9.9M | |
| Research And Development Expense | $6.9M | $5.4M | $2.9M | $2.7M | $1.5M | $1.3M | $1.2M | $1.0M | $847.0K | $1.6M | $5.6M | $2.6M | $4.1M | |
| General And Administrative Expense | $2.2M | $2.9M | $3.3M | $2.6M | $1.4M | $1.4M | $542.0K | $194.0K | $254.0K | $152.0K | $1.7M | $2.0M | $1.3M | |
| Operating Expenses | $9.0M | $8.3M | $6.3M | $5.3M | $2.9M | $2.8M | $1.7M | $1.2M | $1.1M | $1.7M | $7.3M | $4.5M | $5.4M | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$8.7M | -$8.1M | -$6.7M | -$5.1M | -$3.0M | -$2.8M | ||||||||
| Income Tax Expense Benefit | $21.0K | $0.00 | -$544.0K | $0.00 | $0.00 | $0.00 | ||||||||
| Income Taxes Paid Net | $0.00 | $244.0K | ||||||||||||
| Net Income Losses | -$2.8M | -$1.7M | -$2.4M | -$1.1M | -$1.7M | -$7.2M | ||||||||
| Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities | $1.6M | $1.4M | $411.0K | |||||||||||
| Nonoperating Income Expense | ||||||||||||||
| Income Taxes Received | ||||||||||||||
| Restructuring Charges | $79.0K | $670.0K | $247.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $12.3M | $13.5M | $17.0M | $36.2M | $61.5M | $10.8M | $12.4M | $9.8M | -$609.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $7.6M | $6.1M | $9.4M | $13.6M | $15.2M | $11.7M | $12.3M | $7.6M | $1.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $1.4M | -$3.2M | -$4.2M | -$1.6M | $3.5M | -$554.0K | $10.1M | $6.2M | |
| Cash And Cash Equivalents At Carrying Value | $7.6M | $6.1M | $9.3M | $13.5M | $15.2M | $11.7M | $17.6M | $7.5M | |
| Operating Lease Right Of Use Asset | $0.00 | $289.0K | $392.0K | $227.0K | $345.0K | $428.0K | $1.2M | $1.8M | |
| Liabilities | $1.5M | $3.4M | $5.2M | $6.8M | $2.9M | $1.7M | $4.8M | $3.0M | |
| Assets | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M | $12.5M | $19.8M | $12.8M | |
| Retained Earnings Accumulated Deficit | -$111.6M | -$102.6M | -$88.7M | -$63.8M | -$36.2M | -$23.7M | -$105.4M | -$78.3M | |
| Property Plant And Equipment Net | $176.0K | $250.0K | $303.0K | $367.0K | $357.0K | $152.0K | $158.0K | $385.0K | |
| Operating Lease Liability Current | $0.00 | $115.0K | $76.0K | $123.0K | $106.0K | $70.0K | $391.0K | $1.7M | |
| Liabilities Current | $1.5M | $3.2M | $4.8M | $6.7M | $2.7M | $1.3M | $4.1M | $2.7M | |
| Liabilities And Stockholders Equity | $13.8M | $17.0M | $22.2M | $43.1M | $64.4M | $12.5M | $19.8M | $12.8M | |
| Common Stock No Par Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Assets Current | $13.4M | $16.0M | $20.9M | $41.7M | $62.7M | $11.8M | $18.2M | $10.9M | |
| Accounts Payable Trade Current | $485.0K | $633.0K | $516.0K | $1.7M | $1.3M | $93.0K | $875.0K | $396.0K | |
| Operating Lease Liability Noncurrent | $0.00 | $209.0K | $316.0K | $91.0K | $237.0K | $358.0K | $725.0K | ||
| Prepaid Expense And Other Assets Current | $3.1M | $1.7M | $1.0M | $1.8M | $1.5M | $141.0K | $636.0K | ||
| Liabilities Noncurrent | $0.00 | $209.0K | $316.0K | $91.0K | $237.0K | $358.0K | $725.0K | $210.0K | |
| Assets Noncurrent | $387.0K | $924.0K | $1.3M | $1.3M | $1.7M | $637.0K | $1.5M | $1.8M | |
| Employee Related Liabilities Current | $656.0K | $934.0K | $823.0K | $1.6M | $653.0K | $438.0K | |||
| Deposits Assets Current | $2.8M | $8.2M | $10.5M | $26.4M | $46.0M | $24.0K | |||
| Accrued Liabilities Current | $337.0K | $1.5M | $3.4M | $3.4M | $555.0K | $715.0K | |||
| Common Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Restricted Cash Noncurrent | $0.00 | $0.00 | $55.0K | $53.0K | |||||
| Restricted Cash Current | $0.00 | $76.0K | $76.0K | $77.0K | $0.00 | ||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $0.00 | $0.00 | $392.0K | $17.0K | $345.0K | $233.0K | |||
| Treasury Stock Value | $0.00 | $1.2M | $0.00 | ||||||
| Restricted Cash And Cash Equivalents | $0.00 | $130.0K | $120.0K | ||||||
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | $872.0K | $872.0K | $872.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $28.0M | $44.6M | $51.8M | $57.2M | $65.5M | $68.0M | $55.2M | $12.2M | $12.8M | $10.7M | $20.4M | $27.2M | $31.3M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $20.8M | $10.8M | $10.0M | $13.9M | $37.8M | $45.4M | $58.2M | $12.7M | $13.1M | $10.8M | $23.4M | $27.1M | $32.3M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $7.2M | -$1.3M | $46.5M | -$1.4M | $24.6M | ||||||||||
| Cash And Cash Equivalents At Carrying Value | $20.8M | $10.7M | $9.9M | $13.8M | $37.7M | $45.4M | $58.2M | $6.8M | $8.8M | $14.0M | $23.2M | $27.0M | $32.1M | ||
| Operating Lease Right Of Use Asset | $193.0K | $261.0K | $295.0K | $309.0K | $359.0K | $392.0K | $397.0K | $234.0K | $275.0K | $339.0K | |||||
| Liabilities | $7.1M | $5.6M | $4.5M | $3.7M | $1.9M | $2.5M | $5.0M | $2.3M | $1.9M | $3.6M | |||||
| Assets | $35.0M | $50.2M | $56.4M | $61.0M | $67.4M | $70.5M | $60.1M | $7.7M | $10.0M | $15.2M | |||||
| Retained Earnings Accumulated Deficit | -$72.6M | -$55.5M | -$47.5M | -$41.3M | -$31.1M | -$28.2M | -$25.4M | -$114.9M | -$112.4M | -$109.0M | |||||
| Property Plant And Equipment Net | $352.0K | $380.0K | $355.0K | $358.0K | $234.0K | $243.0K | $148.0K | $15.0K | $18.0K | $121.0K | |||||
| Operating Lease Liability Current | $115.0K | $126.0K | $132.0K | $116.0K | $61.0K | $72.0K | $69.0K | $173.0K | $168.0K | $188.0K | |||||
| Liabilities Current | $7.0M | $5.5M | $4.4M | $3.5M | $1.6M | $2.2M | $4.6M | $2.3M | $1.8M | $3.5M | |||||
| Liabilities And Stockholders Equity | $35.0M | $50.2M | $56.4M | $61.0M | $67.4M | $70.5M | $60.1M | $7.7M | $10.0M | $15.2M | |||||
| Common Stock No Par Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Assets Current | $33.8M | $48.7M | $54.8M | $59.3M | $65.8M | $68.8M | $59.5M | $7.4M | $9.7M | $14.7M | |||||
| Accounts Payable Trade Current | $2.2M | $1.2M | $1.4M | $1.5M | $481.0K | $472.0K | $2.1M | $482.0K | $974.0K | $602.0K | |||||
| Operating Lease Liability Noncurrent | $62.0K | $118.0K | $148.0K | $203.0K | $298.0K | $320.0K | $328.0K | $63.0K | $108.0K | $152.0K | |||||
| Prepaid Expense And Other Assets Current | $995.0K | $2.3M | $3.1M | $1.9M | $1.6M | $1.9M | $320.0K | $620.0K | $848.0K | $542.0K | |||||
| Liabilities Noncurrent | $62.0K | $118.0K | $148.0K | $203.0K | $298.0K | $320.0K | $328.0K | ||||||||
| Assets Noncurrent | $1.2M | $1.5M | $1.5M | $1.6M | $1.6M | $1.7M | $600.0K | ||||||||
| Employee Related Liabilities Current | $1.5M | $1.5M | $1.1M | $666.0K | $451.0K | $638.0K | $523.0K | ||||||||
| Deposits Assets Current | $11.9M | $35.7M | $41.8M | $43.6M | $26.5M | $21.5M | $23.0K | ||||||||
| Accrued Liabilities Current | $3.2M | $2.6M | $1.7M | $1.2M | $637.0K | $977.0K | $2.0M | ||||||||
| Common Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Restricted Cash Noncurrent | $77.0K | $77.0K | $85.0K | $53.0K | $53.0K | $51.0K | |||||||||
| Restricted Cash Current | $77.0K | $126.0K | |||||||||||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | |||||||||||||||
| Treasury Stock Value | $1.2M | ||||||||||||||
| Restricted Cash And Cash Equivalents | $0.00 | $0.00 | $126.0K | $130.0K | $130.0K | $130.0K | |||||||||
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | $872.0K | $872.0K | $872.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $623.0K | $617.0K | $1.5M | $3.2M | $2.0M | $130.0K | $1.2M | $1.9M |
| Share Based Compensation | $623.0K | $617.0K | $1.5M | $3.2M | $2.0M | $130.0K | $1.2M | $1.9M |
| Net Cash Provided By Used In Operating Activities | -$11.1M | -$15.4M | -$23.6M | -$20.4M | -$12.4M | -$5.2M | -$16.5M | -$14.2M |
| Net Cash Provided By Used In Investing Activities | $5.4M | $2.3M | $15.9M | $19.5M | -$45.2M | -$62.0K | -$95.0K | -$213.0K |
| Net Cash Provided By Used In Financing Activities | $7.2M | $9.9M | $3.5M | -$808.0K | $61.1M | $4.8M | $26.6M | $20.6M |
| Increase Decrease In Accounts Payable Trade | -$177.0K | $117.0K | -$1.2M | $352.0K | $1.2M | $68.0K | $1.1M | $287.0K |
| Payments To Acquire Property Plant And Equipment | $3.0K | $0.00 | $3.0K | $68.0K | $239.0K | $38.0K | $95.0K | $213.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.1M | $487.0K | -$903.0K | $64.0K | $2.1M | $99.0K | -$2.3M | |
| Increase Decrease In Employee Related Liabilities | -$278.0K | $111.0K | -$737.0K | $907.0K | $215.0K | $194.0K | -$347.0K | $528.0K |
| Increase Decrease In Accrued Liabilities | -$1.2M | -$1.9M | $45.0K | $2.8M | -$1.3M | $392.0K | ||
| Increase Decrease In Operating Lease Liability | -$35.0K | $35.0K | $13.0K | -$11.0K | -$2.0K | |||
| Proceeds From Other Equity | $7.1M | $9.9M | $2.9M | $267.0K | $58.6M | $3.5M | ||
| Proceeds From Stock Options Exercised | $12.0K | $0.00 | $0.00 | $143.0K | $10.0K | |||
| Payments For Investment In Deposits | -$2.3M | -$15.9M | -$19.6M | $46.0M | $24.0K | |||
| Proceeds From Issuance Of Common Stock | $0.00 | $30.5M | $22.9M | |||||
| Proceeds From Sale Of Other Assets Investing Activities | $0.00 | $0.00 | $1.0M | |||||
| Payments Of Stock Issuance Costs | $0.00 | $0.00 | $1.2M | $0.00 | ||||
| Proceeds From Sale Of Treasury Stock | $0.00 | $0.00 | $580.0K | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Share Based Compensation | $484.0K | $836.0K | $761.0K | $874.0K | $441.0K | $527.0K | $43.0K | $23.0K | $28.0K | $46.0K | $321.0K | $368.0K | $380.0K |
| Share Based Compensation | $484.0K | $874.0K | $43.0K | $46.0K | $380.0K | ||||||||
| Net Cash Provided By Used In Operating Activities | -$7.2M | -$3.7M | -$1.3M | -$1.9M | -$3.1M | ||||||||
| Net Cash Provided By Used In Investing Activities | $14.4M | $2.4M | -$2.0K | -$10.0K | -$75.0K | ||||||||
| Net Cash Provided By Used In Financing Activities | $0.00 | $0.00 | $47.8M | $500.0K | $27.8M | ||||||||
| Increase Decrease In Accounts Payable Trade | $529.0K | $151.0K | $281.0K | $37.0K | $704.0K | ||||||||
| Payments To Acquire Property Plant And Equipment | $1.0K | $14.0K | $3.0K | $10.0K | $75.0K | ||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$814.0K | $363.0K | -$57.0K | $52.0K | -$1.5M | ||||||||
| Increase Decrease In Employee Related Liabilities | -$59.0K | $13.0K | $85.0K | -$50.0K | |||||||||
| Increase Decrease In Accrued Liabilities | -$214.0K | $693.0K | -$62.0K | -$204.0K | |||||||||
| Increase Decrease In Operating Lease Liability | -$3.0K | $12.0K | $0.00 | ||||||||||
| Proceeds From Other Equity | $0.00 | $45.4M | |||||||||||
| Proceeds From Stock Options Exercised | |||||||||||||
| Payments For Investment In Deposits | -$1.0K | $0.00 | |||||||||||
| Proceeds From Issuance Of Common Stock | $45.4M | $0.00 | $30.5M | ||||||||||
| Proceeds From Sale Of Other Assets Investing Activities | |||||||||||||
| Payments Of Stock Issuance Costs | |||||||||||||
| Proceeds From Sale Of Treasury Stock |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $0.02 | $0.04 | $0.10 | $0.12 | $0.06 | $0.04 | $0.79 | $1.09 |
| Common Stock Shares Authorized | 4.65B | 4.65B | 650.0M | 650.0M | 650.0M | 500.0M | 100.0M | 100.0M |
| Common Stock Shares Issued | 575.4M | 377.1M | 284.1M | 232.6M | 228.1M | 9.3M | 37.1M | 15.6M |
| Weighted Average Number Of Shares Outstanding Basic | 510.2M | 359.0M | 235.0M | 227.6M | 207.5M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 510.2M | 359.0M | 235.0M | 227.6M | 207.5M | |||
| Earnings Per Share Basic | $0.02 | $0.04 | $0.10 | $0.12 | $0.06 | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 207.5M | 136.8M | 34.4K | 12.6M | ||||
| Common Stock Shares Outstanding | 37.1M | 15.6M | ||||||
| Shares Outstanding | 575.4M | 377.1M | 284.1M | 232.6M | 228.1M | 9.3M | 14.9M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | $0.04 | $0.04 | $0.03 | $0.02 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | -$0.19 | -$0.12 | -$0.38 | |||
| Common Stock Shares Authorized | 650.0M | 650.0M | 650.0M | 650.0M | 650.0M | 650.0M | 650.0M | 500.0M | 500.0M | 100.0M | ||||||
| Common Stock Shares Issued | 232.6M | 229.0M | 228.6M | 228.1M | 228.0M | 228.0M | 214.0M | 37.1M | 37.1M | 37.1M | ||||||
| Weighted Average Number Of Shares Outstanding Basic | 221.0M | 228.8M | 228.2M | 228.1M | 228.0M | 216.3M | ||||||||||
| Weighted Average Number Of Diluted Shares Outstanding | 221.0M | 228.8M | 228.2M | 228.1M | 228.0M | 216.3M | ||||||||||
| Earnings Per Share Basic | $0.04 | $0.04 | $0.03 | $0.02 | $0.01 | $0.01 | ||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 228.1M | 228.0M | 216.3M | 156.8M | 139.4M | 129.8M | 129.8M | 37.1M | 37.1M | 26.3M | ||||||
| Common Stock Shares Outstanding | 232.6M | 232.6M | 229.0M | 228.6M | 228.1M | 228.1M | 228.0M | 228.0M | 214.0M | 9.3M | 37.1M | 37.1M | 37.1M | |||
| Shares Outstanding | ||||||||||||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Finance Income Expenses Net | -$111.0K | $21.0K | -$4.2M | $457.0K | ||||
| Depreciation | $70.0K | $53.0K | $67.0K | $58.0K | $34.0K | $24.0K | $281.0K | $66.0K |
| Additional Paid In Capital | $124.0M | $116.2M | $105.7M | $101.3M | $97.6M | $34.5M | $119.5M | $87.2M |
| Prepaid Expense Noncurrent | $211.0K | $385.0K | $559.0K | $733.0K | $908.0K | $57.0K | $1.1M | |
| Stock And Warrants Issued During Period Value New Issues | $7.2M | $9.9M | $2.9M | $267.0K | $58.6M | $21.9M | ||
| Stock Issued During Period Value Stock Options Exercised | $12.0K | $143.0K | $10.0K | $6.0K | ||||
| Stock Issued During Period Value New Issues | $3.0M | $26.5M | ||||||
| Interest Received | $610.0K | $814.0K | $1.5M | $972.0K | $74.0K | |||
| Adjustments For Finance Costs Net | $0.00 | $4.6M | $709.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q3 2019 | Q2 2019 | Q1 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Finance Income Expenses Net | $317.0K | $237.0K | -$480.0K | $216.0K | -$77.0K | -$17.0K | -$5.0K | $1.0K | $20.0K | $9.0K | $102.0K | $99.0K | $4.5M |
| Depreciation | $16.0K | $13.0K | $7.0K | $5.0K | $21.0K | ||||||||
| Additional Paid In Capital | $101.7M | $100.2M | $99.3M | $98.5M | $96.6M | $96.2M | $80.6M | $119.4M | $119.7M | $119.7M | |||
| Prepaid Expense Noncurrent | $690.0K | $776.0K | $821.0K | $864.0K | $952.0K | $995.0K | |||||||
| Stock And Warrants Issued During Period Value New Issues | $15.1M | $43.5M | |||||||||||
| Stock Issued During Period Value Stock Options Exercised | $32.0K | $29.0K | $562.0K | $125.0K | |||||||||
| Stock Issued During Period Value New Issues | $15.1M | $3.0M | $26.5M | ||||||||||
| Interest Received | |||||||||||||
| Adjustments For Finance Costs Net | $0.00 | $4.6M |
Most recent annual filing with the SEC: March 23, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.